## Debbie L Shawcross

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/542427/publications.pdf

Version: 2024-02-01

144 papers 6,991 citations

66343 42 h-index 81 g-index

144 all docs

144 docs citations

times ranked

144

5907 citing authors

#	Article	IF	Citations
1	Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. Journal of Hepatology, 2022, 76, 332-342.	3.7	79
2	Hepatic encephalopathy and depression in chronic liver disease: is the common link systemic inflammation?. Analytical Biochemistry, 2022, 636, 114437.	2.4	7
3	Implications and Management of Cirrhosisâ€Associated Immune Dysfunction Before and After Liver Transplantation, 2022, 28, 700-716.	2.4	4
4	Statins: A Panacea to Reduce Mortality in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma?. Liver Transplantation, 2022, 28, 357-358.	2.4	1
5	The rise and fall and rise again of ammonia as a therapeutic target in HE. Hepatology, 2022, 75, 1078-1080.	7.3	3
6	Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. Gut, 2022, 71, 1856-1866.	12.1	17
7	Plasma angiopoietin 2 as a novel prognostic biomarker in alcohol-related cirrhosis and hepatitis. Liver Research, 2022, , .	1.4	O
8	Effect of rifaximin on infections, acuteâ€onâ€chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFAâ€AH). Liver International, 2022, 42, 1109-1120.	3.9	20
9	Targeting the gut-liver-immune axis to treat cirrhosis. Gut, 2021, 70, 982-994.	12.1	88
10	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. Journal of Hepatology, 2021, 74, 1097-1108.	3.7	149
11	The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcoholâ€Associated Hepatitis. Liver Transplantation, 2021, 27, 1382-1391.	2.4	4
12	The microbiota in cirrhosis and its role in hepatic decompensation. Journal of Hepatology, 2021, 75, S67-S81.	3.7	107
13	Meeting the Challenge of Antimicrobial Resistance in Cirrhosis: The Invisible Threat That Lies Within. Gastroenterology, 2021, 161, 413-415.	1.3	6
14	Activation and Functional Priming of Blood Neutrophils in Non-Alcoholic Fatty Liver Disease Increases in Non-Alcoholic Steatohepatitis. Clinical and Experimental Gastroenterology, 2021, Volume 14, 441-449.	2.3	7
15	Lessons Learned from Faecal Microbiota Transplantation in Cirrhosis. Current Hepatology Reports, 2020, 19, 159-167.	0.9	3
16	Intestinal Virome in Patients With Alcoholic Hepatitis. Hepatology, 2020, 72, 2182-2196.	7.3	74
17	Ammonia-Induced Brain Edema Requires Macrophage and T Cell Expression of Toll-Like Receptor 9. Cellular and Molecular Gastroenterology and Hepatology, 2019, 8, 609-623.	4.5	11
18	Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all ause admissions in patients on the liver transplant waiting list. Alimentary Pharmacology and Therapeutics, 2019, 50, 435-441.	3.7	43

#	Article	IF	CITATIONS
19	Serum and Fecal Oxylipins in Patients with Alcohol-Related Liver Disease. Digestive Diseases and Sciences, 2019, 64, 1878-1892.	2.3	35
20	Is treating the gut microbiome the key to achieving better outcomes in cirrhosis? Expert Review of Gastroenterology and Hepatology, 2019, 13, 1-2.	3.0	22
21	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. Journal of Hepatology, 2018, 69, 396-405.	3.7	144
22	Editorial: rifaximinâ€"a kick in the gut for spontaneous bacterial peritonitis?. Alimentary Pharmacology and Therapeutics, 2018, 47, 301-303.	3.7	3
23	Plateletâ€leucocyte aggregation is augmented in cirrhosis and further increased by platelet transfusion. Alimentary Pharmacology and Therapeutics, 2018, 47, 1375-1386.	3.7	17
24	Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Alimentary Pharmacology and Therapeutics, 2018, 47, 192-202.	3.7	174
25	Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure. Journal of Critical Care, 2018, 43, 54-60.	2.2	87
26	Mucosa-associated invariant T cells link intestinal immunity with antibacterial immune defects in alcoholic liver disease. Gut, 2018, 67, 918-930.	12.1	106
27	Results of a placebo-controlled double blind randomised trial to investigate the efficacy of rifaximin-alpha versus placebo in improving systemic inflammation in patients with cirrhosis and chronic hepatic encephalopathy (RIFSYS Trial). Journal of Hepatology, 2018, 68, S107-S108.	3.7	1
28	In vitro efficacy of pro―and anticoagulant strategies in compensated and acutely ill patients with cirrhosis. Liver International, 2018, 38, 1988-1996.	3.9	35
29	Rifaximin reduces the incidence of sepsis and all cause admissions whilst on the liver transplant waiting list. Journal of Hepatology, 2018, 68, S119-S120.	3.7	2
30	Editorial: platelet transfusions in cirrhosis—do the risks outweigh the unclear benefits? Authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 1555-1556.	3.7	0
31	Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase. Gut, 2017, 66, 519-529.	12.1	54
32	The impact of rifaximin- $\hat{l}\pm$ on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS). Frontline Gastroenterology, 2017, 8, 243-251.	1.8	26
33	MAIT cell dysfunctions correlate with markers of intestinal integrity in ALD patients. Journal of Hepatology, 2017, 66, S345.	3.7	0
34	Dysfunctional neutrophil effector organelle mobilization and microbicidal protein release in alcohol-related cirrhosis. American Journal of Physiology - Renal Physiology, 2017, 313, G203-G211.	3.4	12
35	Baseline neutrophil to lymphocyte ratio can identify favourable corticosteroid response in alcoholic hepatitis. Journal of Hepatology, 2017, 66, S99.	3.7	4
36	Neutrophil Toll-Like Receptor 9 Expression and the Systemic Inflammatory Response in Acetaminophen-Induced Acute Liver Failure. Critical Care Medicine, 2016, 44, 43-53.	0.9	24

#	Article	IF	Citations
37	Reversal of acquired hepatocerebral degeneration with living donor liver transplantation. Liver Transplantation, 2016, 22, 693-693.	2.4	2
38	The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximinâ€Î±. Liver International, 2016, 36, 1295-1303.	3.9	46
39	How to diagnose and manage hepatic encephalopathy. European Journal of Gastroenterology and Hepatology, 2016, 28, 146-152.	1.6	31
40	The Formation of Activated Platelet-Complexed Leukocytes is Augmented in Cirrhosis and Enhanced by Platelet Transfusion. Journal of Hepatology, 2016, 64, S526-S527.	3.7	0
41	Dramatic Alterations of Anti-Bacterial Mait-Cell Network in Alcoholic Liver Disease. Journal of Hepatology, 2016, 64, S172-S173.	3.7	0
42	Ammonia-Induced Brain Oedema and Immune Dysfunction is Mediated by Toll-Like Receptor 9 (TLR9). Journal of Hepatology, 2016, 64, S314.	3.7	0
43	Altered Gut Microbial Profile is a Proponent of Bacterial Translocation in Acute-on-Chronic Liver Failure. Journal of Hepatology, 2016, 64, S453-S454.	3.7	0
44	Modulation of the Non-Canonical NFKB Pathways may Underlie Alternative Activation of Circulating CD14HI Monocytes in Hyper-Acute Liver Failure. Journal of Hepatology, 2016, 64, S311-S312.	3.7	0
45	PTU-092 Plasma Angiopoietin 2, A Circulating Marker of Endothelial Cell Activation, Is Elevated in Acute Alcoholic Hepatitis. Gut, 2016, 65, A100.1-A100.	12.1	0
46	Effect of prednisolone therapy on monocyte phenotype and function in alcoholic hepatitis. Lancet, The, 2016, 387, S103.	13.7	0
47	Multivariate metabotyping of plasma predicts survival in patients with decompensated cirrhosis. Journal of Hepatology, 2016, 64, 1058-1067.	3.7	77
48	High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial. Journal of Hepatology, 2016, 64, 69-78.	3.7	466
49	Clinical science workshop: targeting the gut-liver-brain axis. Metabolic Brain Disease, 2016, 31, 1327-1337.	2.9	23
50	OC-021ÂMonocyte oxidative burst defect is associated with susceptibility to infection in severe alcoholic hepatitis. Gut, 2015, 64, A11.2-A12.	12.1	1
51	Salivary microbiotaâ€immune profiling in cirrhosis: Could this be the noninvasive strategy that will revolutionize prognostication in hepatology?. Hepatology, 2015, 62, 1001-1003.	7.3	11
52	PWE-088ÂFrequency and function of anti-bacterial mait cells are significantly impaired in advanced alcoholic liver disease. Gut, 2015, 64, A250.2-A251.	12.1	0
53	PWE-114ÂModulation of non-canonical nfkb pathways may underlie the anti-inflammatory, resolution-like activation of circulating cd14hi monocytes in hyper-acute liver failure. Gut, 2015, 64, A262.2-A263.	12.1	0
54	Could abnormal neutrophilâ€platelet interactions and complex formation contribute to oxidative stress and organ failure in cirrhosis?. Hepatology, 2015, 62, 1323-1324.	7.3	5

#	Article	IF	Citations
55	P0168: The impact on hospital resource utilisation of Rifaximin-alpha for hepatic encephalopathy in routine clinical practice: Real world data from seven UK liver centres. Journal of Hepatology, 2015, 62, S366.	3.7	0
56	Blockade of PD1 and TIM3 Restores Innate and Adaptive Immunity in Patients With Acute Alcoholic Hepatitis. Gastroenterology, 2015, 148, 590-602.e10.	1.3	172
57	Increased Survival for Patients With Cirrhosis and Organ Failure in Liver Intensive Care and Validation of the Chronic Liver Failure–Sequential Organ Failure Scoring System. Clinical Gastroenterology and Hepatology, 2015, 13, 1353-1360.e8.	4.4	91
58	P1329 : A placebo controlled single centre double blind randomised trial to investigate the efficacy of rifaximin in improving systemic inflammation and neutrophil malfunction in patients with cirrhosis and chronic hepatic encephalopathy (â€~RIFSYS'). Journal of Hepatology, 2015, 62, S854.	3.7	0
59	Is it time to target gut dysbiosis and immune dysfunction in the therapy of hepatic encephalopathy?. Expert Review of Gastroenterology and Hepatology, 2015, 9, 539-542.	3.0	29
60	Neutrophil vacuolation in acetaminophen-induced acute liver failure. American Journal of Hematology, 2015, 90, 461-461.	4.1	5
61	Acute alcoholic hepatitis and cellular Th1 immune responses to alcohol dehydrogenase. Lancet, The, 2015, 385, S22.	13.7	6
62	Pathogenesis of Hepatic Encephalopathy: Role of Ammonia and Systemic Inflammation. Journal of Clinical and Experimental Hepatology, 2015, 5, S7-S20.	0.9	209
63	Editorial: neutrophil dysfunction in patients with cirrhosis – authors' reply. Alimentary Pharmacology and Therapeutics, 2014, 40, 987-987.	3.7	0
64	Comparison of scoring systems and outcome of patients admitted to a liver intensive care unit of a tertiary referral centre with severe variceal bleeding. Alimentary Pharmacology and Therapeutics, 2014, 39, 1286-1300.	3.7	25
65	Cerebral oedema is rare in acuteâ€onâ€chronic liver failure patients presenting with highâ€grade hepatic encephalopathy. Liver International, 2014, 34, 362-366.	3.9	49
66	The severity of circulating neutrophil dysfunction in patients with cirrhosis is associated with 90â€day and 1â€year mortality. Alimentary Pharmacology and Therapeutics, 2014, 40, 705-715.	3.7	62
67	DOP065 Autoimmune sclerosing cholangitis is associated with small bowel ulceration on capsule enteroscopy. Journal of Crohn's and Colitis, 2014, 8, S46.	1.3	1
68	P305 BLOCKADE OF PD1/TIM3 RESTORES FAVOURABLE IFNγ/IL10 IMMUNE AXIS IN ALCOHOL-RELATED LIVER DISEASE. Journal of Hepatology, 2014, 60, S167.	3.7	0
69	OC-029 Rifaximin Is Efficacious In The Treatment Of Chronic Overt Hepatic Encephalopathy: A Uk Liver Multi-centre Experience. Gut, 2014, 63, A14.2-A15.	12.1	3
70	Recent insights into the pathogenesis of hepatic encephalopathy and treatments. Expert Review of Gastroenterology and Hepatology, 2014, 8, 83-100.	3.0	41
71	P306 MONOCYTE OXIDATIVE BURST DEFECT PREDICTS RISK OF INFECTION IN ALCOHOLIC HEPATITIS. Journal of Hepatology, 2014, 60, S168.	3.7	0
72	P312 UNTARGETED H-NMR SPECTROSCOPY DEMONSTRATES A UNIQUE METABOLIC PHENOTYPE OF ALCOHOLIC HEPATITIS. Journal of Hepatology, 2014, 60, S170.	3.7	0

#	Article	IF	Citations
<b>7</b> 3	P315 PATIENTS WITH ACUTE ALCOHOLIC HEPATITIS PRESENT STRONG CELLULAR Th1 IMMUNE RESPONSES TO ALCOHOL DEHYDROGENASE. Journal of Hepatology, 2014, 60, S171.	3.7	0
74	P314 CHARACTERISATION OF THE PLASMA METABOLIC PHENOTYPE OF ACUTE LIVER FAILURE BY H NMR SPECTROSCOPY. Journal of Hepatology, 2014, 60, S171.	3.7	1
<b>7</b> 5	PWE-143â€Abnormal Platelets And The Formation Of Activated Neutrophil-platelet Complexes Following Platelet Administration Induces Neutrophil Activation And Release Of Reactive Oxygen Species In Liver Cirrhosis. Gut, 2014, 63, A187.2-A188.	12.1	O
76	Systemic inflammation and ammonia in hepatic encephalopathy. Metabolic Brain Disease, 2013, 28, 1-5.	2.9	102
77	552 CIRCULATING NEUTROPHIL GRANULE SUBSET RELEASE IN RESPONSE TO BACTERIAL STIMULUS IS AUGMENTED IN PATIENTS WITH ALCOHOL-RELATED LIVER DISEASE AND MAY CONTRIBUTE TO ORGAN BYSTANDER DAMAGE. Journal of Hepatology, 2013, 58, S225-S226.	3.7	O
78	519 CELLULAR TH1 AND TH2 IMMUNE RESPONSES TO ALCOHOL DEHYDROGENASE WITHIN THE LIVER OF PATIENTS WITH ALCOHOL-RELATED CIRRHOSIS DESPITE ABSTINENCE. Journal of Hepatology, 2013, 58, S213.	3.7	0
79	Alcohol dehydrogenase-specific T-cell responses are associated with alcohol consumption in patients with alcohol-related cirrhosis. Hepatology, 2013, 58, 314-324.	7.3	33
80	547 DOWN-REGULATION OF TOLL-LIKE RECEPTOR-2 AND -4 IN CIRCULATING NEUTROPHILS IN RESPONSE TO SYSTEMIC OXIDATIVE STRESS MAY CONTRIBUTE TO INCREASED SUSCEPTIBILITY TO INFECTION IN ALCOHOLIC HEPATITIS. Journal of Hepatology, 2013, 58, S223-S224.	3.7	0
81	541 SUSCEPTIBILITY TO INFECTION IN PATIENTS WITH ACUTE ALCOHOLIC HEPATITIS: A NOVEL ROLE FOR PD-1 AND GALECTIN-9?. Journal of Hepatology, 2013, 58, S221-S222.	3.7	0
82	Inflammation and hepatic encephalopathy. Archives of Biochemistry and Biophysics, 2013, 536, 189-196.	3.0	114
83	Polymorphisms in ABCB11 and ATP8B1 Associated with Development of Severe Intrahepatic Cholestasis in Hodgkin's Lymphoma. Journal of Clinical and Experimental Hepatology, 2013, 3, 159-161.	0.9	14
84	Acute liver failure and the brain: a look through the crystal ball. Metabolic Brain Disease, 2013, 28, 7-10.	2.9	5
85	Circulating neutrophil dysfunction in acute liver failure. Hepatology, 2013, 57, 1142-1152.	7.3	67
86	Character and Temporal Evolution of Apoptosis in Acetaminophen-Induced Acute Liver Failure*. Critical Care Medicine, 2013, 41, 2543-2550.	0.9	37
87	HYPERGLYCAEMIA WITHIN 14 DAYS OF LIVER TRANSPLANTATION PREDICTS NEW ONSET DIABETES AFTER TRANSPLANTATION (NODAT): Table 1. Gut, 2013, 62, A24.2-A24.	12.1	0
88	Rifaximin is an efficacious treatment for the parkinsonian phenotype of hepatic encephalopathy. Hepatology, 2013, 58, 1516-1517.	7.3	11
89	Pathophysiology of cerebral oedema in acute liver failure. World Journal of Gastroenterology, 2013, 19, 9240.	3.3	109
90	Subacute liver failure secondary to black cohosh leading to liver transplantation. BMJ Case Reports, 2013, 2013, bcr2013009325-bcr2013009325.	0.5	19

#	Article	IF	CITATIONS
91	Neutrophil CD64 Expression Is Elevated in Acetaminophen-induced Acute Liver Failure. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 1058-1059.	5.6	5
92	PMO-125â€Neutrophil intracellular toll-like receptor (TLR) 9 expression serves as a biomarker that determines presence and severity of encephalopathy in acute liver failure and cirrhosis. Gut, 2012, 61, A123.3-A124.	12.1	3
93	PTU-020â€Rifaxamin is a highly efficacious treatment for the parkinsonian phenotype of hepatic encephalopathy (HE). Gut, 2012, 61, A191.2-A192.	12.1	0
94	PTU-009â€Alcohol-induced liver toxicity is associated with neutrophil dysfunction in a novel in-vitro model of acute liver injury. Gut, 2012, 61, A186.2-A186.	12.1	0
95	PTU-040â€Alcohol: always detrimental to the immune system? The role of active alcohol consumption on neutrophil function in alcohol-related cirrhosis. Gut, 2012, 61, A200.1-A200.	12.1	0
96	PTU-045â€Proton nuclear magnetic resonance spectroscopy of plasma in patients with cirrhosis correlates with arterial ammonia but not grade of hepatic encephalopathy. Gut, 2012, 61, A202.2-A202.	12.1	0
97	PTU-016aâ€Functional defects in circulating monocytes may contribute to susceptibility to infection in alcoholic hepatitis: Abstract PTU-016a Figure 1. Gut, 2012, 61, A189.2-A190.	12.1	0
98	PTU-007â€Cerebral oedema is rare in acute-on-chronic liver failure. Gut, 2012, 61, A185.2-A185.	12.1	0
99	99 FUNCTIONAL DEFECTS IN CIRCULATING MONOCYTES MAY CONTRIBUTE TO INCREASED SUSCEPTIBILTY TO INFECTION IN ALCOHOLIC HEPATITIS. Journal of Hepatology, 2012, 56, S43.	3.7	0
100	629 CEREBRAL OEDEMA IS RARE IN ACUTE-ON-CHRONIC LIVER FAILURE (AOCLF). Journal of Hepatology, 2012, 56, S249-S250.	3.7	1
101	1416 PLASMA PHOSHOLIPID PROFILING BY METABONOMICS: HIGHLY ACCURATE OUTCOME PREDICTION IN DECOMPENSATED CIRRHOSIS. Journal of Hepatology, 2012, 56, S557.	3.7	0
102	PTU-046â€Metabolic profiling of plasma by NMR spectroscopy accurately predicts outcome in patients with decompensated cirrhosis and acute on chronic liver failure. Gut, 2012, 61, A202.3-A203.	12.1	1
103	The quest for the elusive factors that underpin neutrophil dysfunction in cirrhosis goes on. Journal of Hepatology, 2012, 56, 1212-1213.	3.7	5
104	The impact of organ dysfunction in cirrhosis: Survival at a cost?. Journal of Hepatology, 2012, 56, 1054-1062.	3.7	522
105	Reply to: "The impact of organ dysfunction in cirrhosis: Survival at a cost?― Journal of Hepatology, 2012, 57, 709.	3.7	0
106	The neurological manifestations of acute liver failure. Neurochemistry International, 2012, 60, 662-671.	3.8	70
107	CD14, CD16 and HLAa€DR reliably identifies numan monocytes and their subsets in the context of pathologically reduced HLAâ€DR expression by CD14 <sup>hi</sup> /CD16 <sup>monocytes: Expansion of CD14<sup>hi</sup>/CD16<sup>pos</sup> and contraction of CD14<sup>/CD16<sup>pos</sup> monocytes in acute liver failure. Cytometry Part A: the</sup></sup>	1.5	182
108	Journal of the International Society for Analytical Cytology, 2012, 61A, 623-634.  PWE-290â€Active alcohol consumption induces functional immune paresis but paradoxically promotes endotoxin tolerance in those with advanced alcohol-related cirrhosis. Gut, 2012, 61, A416.1-A416.	12.1	0

#	Article	IF	CITATIONS
109	Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. Journal of Hepatology, 2011, 54, 640-649.	3.7	224
110	175 UTILITY OF ORGAN FAILURE PROGNOSTIC SCORING SYSTEMS IN A LARGE COHORT OF CRITICALLY ILL PATIENTS WITH CIRRHOSIS: IMPROVED PREDICTION OF IN-HOSPITAL MORTALITY OVER MELD. Journal of Hepatology, 2011, 54, S75.	3.7	1
111	192 THE EXCESS MORTALITY ASSOCIATED WITH BETA-BLOCKER THERAPY IN PATIENTS WITH DIURETIC INTOLERANT ASCITES CAN BE EXPLAINED BY WORSENING NEUTROPHIL DYSFUNCTION. Journal of Hepatology, 2011, 54, S82.	3.7	O
112	Review article: the design of clinical trials in hepatic encephalopathy - an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Alimentary Pharmacology and Therapeutics, 2011, 33, 739-747.	3.7	285
113	Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology, 2010, 51, 1062-1069.	7.3	162
114	Neutrophil gelatinase-Associated lipocalin predicts acute kidney injury in patients undergoing liver transplantation. Liver Transplantation, 2010, 16, 1257-1266.	2.4	85
115	PWE-041â€Mannose binding lectin deficiency as a predictor of severity, disease progression and outcome following paracetamol-induced acute liver failure. Gut, 2010, 59, A101.1-A101.	12.1	0
116	PWE-056â€A compensatory anti-inflammatory response syndrome triggered by neutrophil-induced oxidative stress is associated with chronic low grade hepatic encephalopathy in patients with advanced cirrhosis. Gut, 2010, 59, A107.1-A107.	12.1	0
117	PWE-057 Impaired neutrophil phagocytic capacity in patients with advanced cirrhosis is related to the development of ammonia-induced neutrophil swelling. Gut, 2010, 59, A107.2-A107.	12.1	0
118	PWE-046â€Factors that influence outcome of patients with severe upper gastrointestinal variceal bleeding. A single centre experience. Gut, 2010, 59, A103.1-A103.	12.1	0
119	The 6-month abstinence rule in liver transplantation. Lancet, The, 2010, 376, 216-217.	13.7	47
120	Changing face of hepatic encephalopathy: Role of inflammation and oxidative stress. World Journal of Gastroenterology, 2010, 16, 3347.	3.3	108
121	A dent in our sobriety. BMJ: British Medical Journal, 2009, 338, b1737-b1737.	2.3	2
122	Acute-on-Chrenic Liver Failure in Cirrhosis: Defining and Managing Organ Dysfunction., 2009,, 658-671.		2
123	Ammonia impairs neutrophil phagocytic function in liver disease. Hepatology, 2008, 48, 1202-1212.	7.3	139
124	Lamotrigine and the risk of fulminant hepatic failure. Lancet, The, 2008, 371, 649-650.	13.7	8
125	312 DEFINING THE IMPACT OF ORGAN DYSFUNCTION IN CIRRHOSIS: SURVIVAL AT A COST?. Journal of Hepatology, 2008, 48, S124.	3.7	0
126	Outcome of patients with cirrhosis admitted to intensive care. Current Opinion in Critical Care, 2008, 14, 202-207.	3.2	24

#	Article	IF	Citations
127	Old versus new antiepileptic drugs: the SANAD study. Lancet, The, 2007, 370, 314-315.	13.7	11
128	Endotoxemia produces coma and brain swelling in bile duct ligated rats. Hepatology, 2007, 45, 1517-1526.	7.3	182
129	Role of ammonia and inflammation in minimal hepatic encephalopathy. Metabolic Brain Disease, 2007, 22, 125-138.	2.9	219
130	Brain cytokine flux in acute liver failure and its relationship with intracranial hypertension. Metabolic Brain Disease, 2007, 22, 375-388.	2.9	113
131	The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation. Cellular and Molecular Life Sciences, 2005, 62, 2295-2304.	5.4	199
132	Ammonia and Hepatic Encephalopathy: The More Things Change, the More They Remain the Same. Metabolic Brain Disease, 2005, 20, 169-179.	2.9	65
133	Treatment of hepatic encephalopathy. Lancet, The, 2005, 365, 1385-1386.	13.7	4
134	Dispelling myths in the treatment of hepatic encephalopathy. Lancet, The, 2005, 365, 431-433.	13.7	104
135	Low myo-inositol and high glutamine levels in brain are associated with neuropsychological deterioration after induced hyperammonemia. American Journal of Physiology - Renal Physiology, 2004, 287, G503-G509.	3.4	65
136	Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy. Hepatology, 2004, 39, 471-475.	7.3	118
137	Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. Journal of Hepatology, 2004, 40, 247-254.	3.7	469
138	193 Aseptic inflammation independent of its source is important in the development of advanced grades of encephalopathy in alcoholic cirrhosis. Journal of Hepatology, 2004, 40, 63.	3.7	0
139	Should a biopsy precede liver resection or transplantation for presumed hepatocellular carcinoma when the alfa fetoprotein is normal?. Transplantation, 2004, 77, 637-638.	1.0	5
140	Treatment of hepatic encephalopathy: It's not lactulose. BMJ: British Medical Journal, 2004, 329, 112.1.	2.3	12
141	Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. Journal of Hepatology, 2003, 38, 419-425.	3.7	221
142	The molecular pathogenesis of hepatic encephalopathy. International Journal of Biochemistry and Cell Biology, 2003, 35, 1175-1181.	2.8	82
143	Decompensation of chronic stable alcoholic liver disease by severe exfoliative dermatitis. European Journal of Gastroenterology and Hepatology, 2003, 15, 433-435.	1.6	0
144	Delayed opioid withdrawal-like reaction in primary biliary cirrhosis following naloxone therapy. Gastroenterology, 2001, 121, 743-744.	1.3	10